Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 3/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.33 |
| ▸ | MET | P08581 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25113804 | 0.84 | CCR1 (0.40) | RXRAGRIN1GRIN2B | |
| SCHEMBL26762020 | 0.84 | ALDH1A1 (0.40) | NPC1RAB9A | |
| SCHEMBL26762016 | 0.77 | ALDH1A1 (0.34) | — | |
| SCHEMBL23905520 | 0.77 | CCR1 (0.41) | RXRAGRIN1GRIN2B | |
| SCHEMBL26762031 | 0.71 | PDE10A (0.33) | RXRAGRIN1GRIN2B | |
| SCHEMBL21585394 | 0.68 | RXRA (0.38) | RXRAGRIN1GRIN2BMETNPC1 | |
| SCHEMBL16648664 | 0.66 | RXRA (0.34) | RXRAGRIN1GRIN2BMETNPC1 | |
| SCHEMBL189205 | 0.66 | PIK3CA (0.37) | RXRAGRIN1GRIN2BMET | |
| SCHEMBL10141672 | 0.66 | MAP3K12 (0.45) | — | |
| SCHEMBL23905240 | 0.66 | P2RX3 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365525-A1 | ANTIVIRAL COMPOUNDS | ENANTA PHARMACEUTICALS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230365525-A1 | ANTIVIRAL COMPOUNDS | ENANTA PHARMACEUTICALS, INC. | 2023-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365525-A1 | ANTIVIRAL COMPOUNDS | ACE, ZC3HAV1, SARS1 | RXRA 2401/4885GRIN1 3700/4885GRIN2B 4162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.